{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Gainesville&page=46&state=Florida", "query": { "state": "Florida", "city": "Gainesville", "page": 46 }, "page_size": 10 }, "pagination": { "page": 46, "page_size": 10, "total_count": 5273, "total_pages": 528, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Gainesville&page=47&state=Florida&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Gainesville&page=45&state=Florida&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-02T16:48:45.023Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02839707", "title": "Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Fallopian Tube High Grade Serous Adenocarcinoma", "Ovarian High Grade Serous Adenocarcinoma", "Ovarian Seromucinous Carcinoma", "Primary Peritoneal High Grade Serous Adenocarcinoma", "Recurrent Fallopian Tube Carcinoma", "Recurrent Fallopian Tube Clear Cell Adenocarcinoma", "Recurrent Fallopian Tube Endometrioid Adenocarcinoma", "Recurrent Fallopian Tube Undifferentiated Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Ovarian Clear Cell Adenocarcinoma", "Recurrent Ovarian Endometrioid Adenocarcinoma", "Recurrent Ovarian Undifferentiated Carcinoma", "Recurrent Platinum-Resistant Fallopian Tube Carcinoma", "Recurrent Platinum-Resistant Ovarian Carcinoma", "Recurrent Platinum-Resistant Primary Peritoneal Carcinoma", "Recurrent Primary Peritoneal Carcinoma", "Recurrent Primary Peritoneal Clear Cell Adenocarcinoma", "Recurrent Primary Peritoneal Endometrioid Adenocarcinoma", "Recurrent Primary Peritoneal Undifferentiated Carcinoma" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Pegylated Liposomal Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 444, "start_date": "2017-06-23", "completion_date": "2027-05-11", "has_results": true, "last_update_posted_date": "2026-10-26", "last_synced_at": "2026-11-02T16:48:45.023Z", "location_count": 907, "location_summary": "Anchorage, Alaska • Fairbanks, Alaska • Goodyear, Arizona + 574 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT02839707" }, { "nct_id": "NCT06161571", "title": "A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "NASH/MASH", "NAFLD/MASLD" ], "interventions": [ { "name": "Efruxifermin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Akero Therapeutics, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 700, "start_date": "2023-11-10", "completion_date": "2026-06-19", "has_results": false, "last_update_posted_date": "2026-04-30", "last_synced_at": "2026-11-02T16:48:45.023Z", "location_count": 139, "location_summary": "Birmingham, Alabama • Chandler, Arizona • Flagstaff, Arizona + 117 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Flagstaff", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06161571" }, { "nct_id": "NCT01508910", "title": "Efficacy and Safety of Targeted Intramyocardial Delivery of Auto CD34+ Stem Cells for Improving Exercise Capacity in Subjects With Refractory Angina", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Myocardial Ischemia", "Refractory Angina Pectoris", "Advanced Coronary Heart Disease" ], "interventions": [ { "name": "Auto-CD34+ cells", "type": "BIOLOGICAL" }, { "name": "Placebo: Diluent used to suspend Auto-CD34+ cells", "type": "BIOLOGICAL" }, { "name": "Standard of care", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Lisata Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "21 Years to 80 Years" }, "enrollment_count": 291, "start_date": "2012-04", "completion_date": "2015-11", "has_results": true, "last_update_posted_date": "2018-12-19", "last_synced_at": "2026-11-02T16:48:45.023Z", "location_count": 41, "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 38 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01508910" }, { "nct_id": "NCT02282527", "title": "A Study to Assess Safety and PK of Liquid Alpha₁-Proteinase Inhibitor (Human) in Treating Alpha₁-Antitrypsin Deficiency", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Alpha₁-Antitrypsin Deficiency" ], "interventions": [ { "name": "Liquid Alpha₁-PI", "type": "BIOLOGICAL" }, { "name": "Prolastin-C", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Grifols Therapeutics LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 32, "start_date": "2014-10", "completion_date": "2016-01", "has_results": true, "last_update_posted_date": "2017-03-13", "last_synced_at": "2026-11-02T16:48:45.023Z", "location_count": 6, "location_summary": "Denver, Colorado • Gainesville, Florida • Miami, Florida + 3 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Wilmington", "state": "North Carolina" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT02282527" }, { "nct_id": "NCT00617461", "title": "A Clinical Study in Subjects With Neuropathic Pain From PHN Who Have Had an Inadequate Response to Gabapentin Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neuralgia, Postherpetic" ], "interventions": [ { "name": "GEn 1200mg/day", "type": "DRUG" }, { "name": "GEn 3600mg/day", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "XenoPort, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 96, "start_date": "2008-03", "completion_date": "2009-07", "has_results": true, "last_update_posted_date": "2013-07-22", "last_synced_at": "2026-11-02T16:48:45.023Z", "location_count": 42, "location_summary": "Phoenix, Arizona • Oxnard, California • Roseville, California + 36 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Oxnard", "state": "California" }, { "city": "Roseville", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Bradenton", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00617461" }, { "nct_id": "NCT01128270", "title": "Pharmacotoxicology of Trichloroethylene Metabolites", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Dichloroacetate environmental dose", "type": "DRUG" }, { "name": "Chloral Hydrate environmental dose", "type": "DRUG" }, { "name": "Dichloroacetate therapeutic dose", "type": "DRUG" }, { "name": "Chloral Hydrate therapeutic dose", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Florida", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "21 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "21 Years to 50 Years" }, "enrollment_count": 27, "start_date": "2010-04", "completion_date": "2012-10", "has_results": true, "last_update_posted_date": "2014-05-07", "last_synced_at": "2026-11-02T16:48:45.023Z", "location_count": 1, "location_summary": "Gainesville, Florida", "locations": [ { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01128270" }, { "nct_id": "NCT03556020", "title": "Phase 2 Study to Assess Safety, Tolerability and Efficacy of Once Weekly SC Pemziviptadil (PB1046) in Subjects With Symptomatic PAH", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pulmonary Arterial Hypertension" ], "interventions": [ { "name": "Pemziviptadil (PB1046)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "PhaseBio Pharmaceuticals Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "79 Years", "sex": "ALL", "summary": "18 Years to 79 Years" }, "enrollment_count": 35, "start_date": "2018-07-15", "completion_date": "2022-01-07", "has_results": false, "last_update_posted_date": "2022-08-23", "last_synced_at": "2026-11-02T16:48:45.023Z", "location_count": 26, "location_summary": "Mobile, Alabama • Tucson, Arizona • La Jolla, California + 19 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03556020" }, { "nct_id": "NCT01464827", "title": "ABT-450 With Ritonavir and ABT-267 and/or ABT-333 With and Without Ribavirin in Genotype 1 Hepatitis C Virus Infected Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Hepatitis C", "Hepatitis C (HCV)", "Hepatitis C Genotype 1" ], "interventions": [ { "name": "ABT-450", "type": "DRUG" }, { "name": "ABT-333", "type": "DRUG" }, { "name": "ABT-267", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" }, { "name": "Ritonavir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie (prior sponsor, Abbott)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 580, "start_date": "2011-10", "completion_date": "2013-09", "has_results": true, "last_update_posted_date": "2015-04-22", "last_synced_at": "2026-11-02T16:48:45.023Z", "location_count": 60, "location_summary": "Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 52 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Dothan", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01464827" }, { "nct_id": "NCT02270983", "title": "Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Opioid-Induced Constipation" ], "interventions": [ { "name": "Linaclotide 145 micrograms", "type": "DRUG" }, { "name": "Linaclotide 290 micrograms", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Forest Laboratories", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 254, "start_date": "2014-10-31", "completion_date": "2015-10-31", "has_results": true, "last_update_posted_date": "2019-04-08", "last_synced_at": "2026-11-02T16:48:45.023Z", "location_count": 77, "location_summary": "Anniston, Alabama • Foley, Alabama • Phoenix, Arizona + 67 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Foley", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "North Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02270983" }, { "nct_id": "NCT02703597", "title": "Smoking Prevention Through Social Connections Among Adolescents - ASPIRE", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Tobacco Use Behavior" ], "interventions": [ { "name": "Surveys", "type": "BEHAVIORAL" }, { "name": "ASPIRE", "type": "BEHAVIORAL" }, { "name": "GSA-ASPIRE-Network", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of Florida", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "11 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "11 Years to 18 Years" }, "enrollment_count": 393, "start_date": "2021-06-01", "completion_date": "2022-03-16", "has_results": true, "last_update_posted_date": "2024-10-23", "last_synced_at": "2026-11-02T16:48:45.023Z", "location_count": 1, "location_summary": "Gainesville, Florida", "locations": [ { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02703597" } ] }